200933-25-1 Usage
General Description
(METHOXY)(3-NITROPYRIDIN-2-YL)METHANOL is a chemical compound with the molecular formula C8H8N2O4. It is a derivative of 3-nitropyridine and contains a methoxy group. (METHOXY)(3-NITROPYRIDIN-2-YL)METHANOL is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and organic compounds. It can also be used as a reagent in chemical reactions and as a precursor for the preparation of other organic molecules. The presence of the nitro group in the molecule makes it a potentially hazardous chemical and proper safety precautions should be taken when handling and storing it. Overall, (METHOXY)(3-NITROPYRIDIN-2-YL)METHANOL is an important intermediate in organic synthesis with various industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 200933-25-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,0,9,3 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 200933-25:
(8*2)+(7*0)+(6*0)+(5*9)+(4*3)+(3*3)+(2*2)+(1*5)=91
91 % 10 = 1
So 200933-25-1 is a valid CAS Registry Number.
200933-25-1Relevant articles and documents
THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS
-
Page/Page column 52, (2009/03/07)
The present invention is directed to novel thieno[2,3-d]pyrimidin-4(3H)-one, isoxazolo[5,4-d]pyrimidin-4(5H)-one and isothiazolo[5,4-d]pyrimidin-4(5H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula (I), wherein the variables R1, R2, R3, X and Z are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.